<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290732</url>
  </required_header>
  <id_info>
    <org_study_id>J0503 CDR0000459502</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0503</secondary_id>
    <nct_id>NCT00290732</nct_id>
  </id_info>
  <brief_title>Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer</brief_title>
  <official_title>A Phase I Study Assessing the Feasibility and Safety of Intraductal Administration of Pegylated Liposomal Doxorubicin (Doxil) in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways
      to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill more
      tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the
      amount of normal tissue that needs to be removed.

      PURPOSE: This phase I trial is studying the side effects and best dose of liposomal
      doxorubicin when given before mastectomy in treating women with invasive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the feasibility, safety, and maximum tolerated dose of intraductal pegylated
           doxorubicin HCl liposome in women with invasive breast cancer awaiting mastectomy.

      Secondary

        -  Determine the pharmacokinetics of intraductal pegylated doxorubicin HCl liposome,
           including serial plasma concentrations of doxorubicin and doxorubicinol and tissue
           concentrations in different portions of the breast at the time of surgery.

      OUTLINE: This is a dose-escalation study.

      Patients receive an intraductal injection of pegylated doxorubicin HCl liposome* on day 1.
      Patients undergo mastectomy 2-4 weeks later.

      Cohorts of 3-6 patients receive escalating doses of pegylated doxorubicin HCl liposome* until
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that
      at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are
      treated at the MTD.

      NOTE: *The first cohort of 3 patients receive intraductal dextrose only followed by surgery
      as a feasibility study. An additional 3 patients receiving intravenous PLD will be enrolled
      in a pharmacokinetic control portion of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Until up to 30 days after PLD administration</time_frame>
    <description>Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Doxorubicin in Blood (Plasma) at Definitive Surgery</measure>
    <time_frame>Baseline, 4 hrs, day2/24 hrs, day 8, day of surgery/biopsy</time_frame>
    <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in blood (plasma) across all the participants in each group is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Doxorubicin in Tissue at Definitive Surgery</measure>
    <time_frame>Day of surgery/biopsy</time_frame>
    <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in tissue across all the participants in each group is reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Intraductal arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraductal arm</intervention_name>
    <description>Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter</description>
    <arm_group_label>Intraductal arm</arm_group_label>
    <other_name>Doxorubicin HCl Liposome Injection, Dox-SL, Doxil TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous arm</intervention_name>
    <description>Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.</description>
    <arm_group_label>Intravenous arm</arm_group_label>
    <other_name>Doxorubicin HCl Liposome Injection, Dox-SL, Doxil TM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed infiltrating carcinoma of the breast meeting any of the
             following criteria:

               -  T1-3, any N disease

               -  Proven ductal carcinoma in situ

          -  Unresected disease

               -  Planned mastectomy as definitive surgical procedure

                    -  Known or suspected metastatic disease allowed provided mastectomy is planned

          -  Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative
             therapy)

          -  No inflammatory breast cancer or other T4 features

          -  Successful baseline ductogram

               -  Baseline nipple aspiration procedure must identify a duct productive of nipple
                  aspirate fluid

               -  No severe nipple retraction

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female patients

          -  Menopausal status not specified

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Creatinine ≤ 2 times upper limit of normal (ULN)

          -  Bilirubin ≤ 2 times ULN

          -  AST and ALT ≤ 2.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No significant history of severe allergy to iodinated contrast material or
             debilitating anxiety that may not allow for a ductogram

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior preoperative chemotherapy, trastuzumab (Herceptin®), or hormonal therapy allowed
             provided it was completed 7-14 days prior to study treatment

          -  No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or
             breast implant (present or past history of implant that was removed)

          -  No other prior procedure that may have altered the breast ductal system in the
             ipsilateral breast

          -  No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents
             for breast cancer

          -  No other concurrent investigational drugs

          -  Concurrent bisphosphonates allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med. 2011 Oct 26;3(106):106ra108. doi: 10.1126/scitranslmed.3002368.</citation>
    <PMID>22030751</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>March 1, 2013</results_first_submitted>
  <results_first_submitted_qc>July 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2013</results_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From February 2006 to October 2009, 19 women signed consent, and 17 women were enrolled in the intraductal portion of the study. An addition 3 women receiving standard intravenous PLD were enrolled in a pharmacokinetic contract portion.</recruitment_details>
      <pre_assignment_details>Participants were not included after consent if eligibility criteria were not met (eg, lab values, performance status); an additional 2 subjects were consented but not included in the study population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Intraductal Arm- 0 mg PLD</title>
          <description>Participants received intraductal administration of dextrose prior to conventional surgery for breast cancer.</description>
        </group>
        <group group_id="P2">
          <title>Intraductal Arm- 2 mg PLD</title>
          <description>Participants received intraductal administration of pegylated liposomal doxorubicin hydrochloride (or PLD), 2 mg, prior to conventional surgery for breast cancer.</description>
        </group>
        <group group_id="P3">
          <title>Intraductal Arm- 5 mg PLD</title>
          <description>Participants received intraductal administration of pegylated liposomal doxorubicin hydrochloride (or PLD), 5 mg, prior to conventional surgery for breast cancer.</description>
        </group>
        <group group_id="P4">
          <title>Intraductal Arm- 10 mg PLD</title>
          <description>Participants received intraductal administration of pegylated liposomal doxorubicin hydrochloride (or PLD), 10 mg, prior to conventional surgery for breast cancer.</description>
        </group>
        <group group_id="P5">
          <title>Intravenous Arm</title>
          <description>Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inability to instill drug intraductally.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intraductal Arm</title>
          <description>Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous Arm</title>
          <description>Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD)</title>
        <description>Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients.</description>
        <time_frame>Until up to 30 days after PLD administration</time_frame>
        <population>Participants received intraductal administration of dextrose prior to conventional surgery for breast cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Intraductal Arm</title>
            <description>Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD)</title>
          <description>Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients.</description>
          <population>Participants received intraductal administration of dextrose prior to conventional surgery for breast cancer.</population>
          <units>milligrams</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Doxorubicin in Blood (Plasma) at Definitive Surgery</title>
        <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in blood (plasma) across all the participants in each group is reported.</description>
        <time_frame>Baseline, 4 hrs, day2/24 hrs, day 8, day of surgery/biopsy</time_frame>
        <population>Participants in whom blood and/or tissue samples were collected at surgery or breast biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Intraductal Arm- 0 mg PLD</title>
            <description>Participants received intraductal administration of dextrose prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Intraductal Arm- 2 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 2 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Intraductal Arm- 5 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 5 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Intraductal Arm- 10 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 10 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O5">
            <title>Intravenous Arm</title>
            <description>Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Doxorubicin in Blood (Plasma) at Definitive Surgery</title>
          <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in blood (plasma) across all the participants in each group is reported.</description>
          <population>Participants in whom blood and/or tissue samples were collected at surgery or breast biopsy.</population>
          <units>nM</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Doxorubicin, max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="28.5"/>
                    <measurement group_id="O3" value="18.3"/>
                    <measurement group_id="O4" value="902.0"/>
                    <measurement group_id="O5" value="79300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Doxorubicinol, max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="36.9"/>
                    <measurement group_id="O5" value="8090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Doxorubicin in Tissue at Definitive Surgery</title>
        <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in tissue across all the participants in each group is reported.</description>
        <time_frame>Day of surgery/biopsy</time_frame>
        <population>Participants in whom blood and/or tissue samples were collected at surgery or breast biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Intraductal Arm- 0 mg PLD</title>
            <description>Participants received intraductal administration of dextrose prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O2">
            <title>Intraductal Arm- 2 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 2 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O3">
            <title>Intraductal Arm- 5 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 5 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O4">
            <title>Intraductal Arm- 10 mg PLD</title>
            <description>Participants received intraductal administration of dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD), 10 mg, prior to conventional surgery for breast cancer.</description>
          </group>
          <group group_id="O5">
            <title>Intravenous Arm</title>
            <description>Participants receiving standard intravenous administration of pegylated liposomal doxorubicin prior to breast biopsy for drug concentrations.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Doxorubicin in Tissue at Definitive Surgery</title>
          <description>Due to the limited number of samples and detectable levels, the maximum concentration of doxorubicin in tissue across all the participants in each group is reported.</description>
          <population>Participants in whom blood and/or tissue samples were collected at surgery or breast biopsy.</population>
          <units>nmol/g</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Doxorubicin, max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.73"/>
                    <measurement group_id="O4" value="10.82"/>
                    <measurement group_id="O5" value="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Doxorubicinol, max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.09"/>
                    <measurement group_id="O4" value="5.26"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After definitive surgery</time_frame>
      <desc>Note: Adverse events were not collected in the intravenous group/arm; only the concentration of doxorubicin in tissue applied to this group of participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intraductal Arm- 0 mg PLD</title>
        </group>
        <group group_id="E2">
          <title>Intraductal Arm- 2 mg PLD</title>
        </group>
        <group group_id="E3">
          <title>Intraductal Arm- 5 mg PLD</title>
        </group>
        <group group_id="E4">
          <title>Intraductal Arm- 10 mg PLD</title>
        </group>
        <group group_id="E5">
          <title>Intravenous Arm</title>
          <description>Note: Adverse events were not collected in the intravenous group/arm; only the concentration of doxorubicin in tissue applied to this group of participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology other (right areolar eschar)</sub_title>
                <description>Eschar/necrosis in the region of the remaining areola of the right breast post-mastectomy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast fullness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Breast or nipple pain/discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Duct cannulation was not successful in all participants; possibly due to extensive disease or prior excisional biopsy (2 subjects).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Vered Stearns</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>4432876489</phone>
      <email>vstearn1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

